FDA Approved: VYVANSE — Supplemental Application (Takeda Pharmaceuticals America, Inc.)

View source ↗

Summary

FDA approved a supplemental NDA for Vyvanse (lisdexamfetamine dimesylate) from Takeda Pharmaceuticals America, detailing a label/indication update.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder
• Binge Eating Disorder

Drugs mentioned

• Vyvanse (lisdexamfetamine dimesylate)

Snippet

SUPPL AP for VYVANSE (LISDEXAMFETAMINE DIMESYLATE)